Agreements reached under this partnership
Business alliance- 1
Acquisition of exclusive rights to develop, manufacture and market the compound in Japan, South Korea and Taiwan
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
Milestone payments have been established based on the achievement of certain net sales targets, but the sales figures and achievement dates are not disclosed.
The upfront payment to be made to BIODOL under this agreement is expected to be recorded as selling, general and administrative expenses (research and development expenses) for the fiscal year ending March 2026. If any matter requiring timely disclosure arises, it will be promptly announced.
| Item | Details |
|---|---|
| Name of alliance partner | BIODOL Therapeutics |
| Alliance partner's business activities | BIODOL aims to develop first-in-class pain treatments and is focused on developing allosteric inhibitors of the FLT3 receptor. |
| Alliance partner's location | Montarnaud, France |
| Type of alliance | Business alliance |
| Details of the alliance | Acquisition of exclusive rights to develop, manufacture and market the compound in Japan, South Korea and Taiwan |
| Numerical targets under the alliance | Milestone payments have been established based on the achievement of certain net sales targets, but the sales figures and achievement dates are not disclosed. |
| Contract Date | 31 March 2026 |
| Impact on Business Performance | The upfront payment to be made to BIODOL under this agreement is expected to be recorded as selling, general and administrative expenses (research and development expenses) for the fiscal year ending March 2026. If any matter requiring timely disclosure arises, it will be promptly announced. |
Items this document does not state (15)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To provide valuable new medicines that address unmet medical needs and offer new treatment options to patients suffering from pain.